Welcome to our dedicated page for American Express Co SEC filings (Ticker: AXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Express’s closed-loop network produces a flood of granular data—loan loss reserves, billed business growth, discount revenue margins—that shows up first in its SEC filings. If you have ever asked, “Where can I find American Express’s quarterly earnings report 10-Q filing?� or “How do I track American Express insider trading Form 4 transactions in real time?�, you are in the right place.
Stock Titan decodes every disclosure the moment it posts to EDGAR. Our AI reads the 300-page annual report so you can jump straight to cardmember credit metrics, co-brand partner economics and segment ROE, turning the dense 10-K into a clear narrative of what drives AXP’s returns. Short on time? The platform delivers concise explanations of each 8-K material event, from merchant fee updates to reserve builds, and flags any accounting change immediately.
Form 4 insider filings are streamed within seconds, letting you monitor American Express Form 4 insider transactions real-time—ideal for spotting when executives exercise options or trim exposure ahead of network fee announcements. Proxy statements reveal executive compensation designs tied to revenue per cardmember; our summary highlights those incentives, so you can assess alignment quickly.
- American Express annual report 10-K simplified—understand discount revenue trends
- American Express quarterly earnings report 10-Q filing with AI-generated KPI dashboards
- American Express 8-K material events explained—partner program renewals, capital actions
- American Express proxy statement executive compensation insights
Whether you need an American Express earnings report filing analysis for valuation, or guidance for understanding American Express SEC documents with AI, this page delivers every filing, every update, and every insight—without the jargon.
Form 4 filing summary � KeyCorp (KEY), 07/01/2025: Director Barbara R. Snyder converted 35,955 deferred shares (transaction code M) into an equal number of common shares. The conversion increased her directly held common-share position to 71,632 shares. No open-market purchase or sale price was reported because the shares derive from KeyCorp’s Directors� Deferred Share Sub-Plan, where each deferred share is economically equivalent to a common share. Following the transaction, Snyder still holds 177,901 deferred shares that remain subject to the plan. The filing also notes that direct ownership totals include roughly 175 common shares obtained through the June 2025 dividend-reinvestment program, and deferred-share holdings include about 2,765 dividend-equivalent units accrued during the same period. As there was no disposition of shares and the transaction merely settles a long-standing equity award, the impact on KeyCorp’s public float and insider sentiment is modest.
Cardlytics, Inc. (CDLX) â€� Form 144 filing indicates an insider intends to sell 5,271 common shares on or about 02-Jul-2025 through Fidelity Brokerage on Nasdaq. The proposed sale represents â‰�0.01&˛Ô˛ú˛ő±č;% of the company’s 52.5 million shares outstanding and carries an estimated market value of $9,396.
The filer—identified in the past-sales section as Nicholas Lynton—previously sold 6,057 shares in two transactions during April 2025, generating gross proceeds of $10,852. The shares to be sold were acquired via restricted-stock vesting on 01-Jul-2025 and are being disposed of for personal account purposes; no cash outlay was involved in the acquisition (classified as compensation).
Because the volume is immaterial relative to the float and no undisclosed adverse information is asserted, the filing is generally routine. Nonetheless, it signals continued insider selling within a three-month window, which investors may monitor for sentiment trends rather than fundamental impact.
InnovAge Holding Corp. (INNV) filed a Form 4 disclosing that director Edward M. Kennedy Jr. received 25,316 Restricted Stock Units (RSUs) on July 1, 2025. The award was recorded at a purchase price of $0 because RSUs are equity compensation rather than open-market purchases.
The RSUs will vest in full on June 30, 2026, provided the director remains in service through that date. Upon settlement, the units will convert into an equivalent number of common shares. Following the grant, Kennedy’s direct beneficial ownership totals 68,157 shares of InnovAge common stock.
No sales, option exercises, derivative positions, or other transactions were reported. The filing therefore reflects a routine equity-compensation grant that modestly increases insider alignment but does not involve immediate cash inflows, earnings information, or strategic developments.
The Form 4 filing reports that Chemours Company (CC) director Courtney Mather was awarded 2,292 deferred stock units (DSUs) on 30 June 2025. Each DSU equals one share of common stock and will be settled in the first month after the director leaves the board. The award is recorded at a reference price of $11.45 per unit. After the grant, Mather directly owns 2,292 derivative securities; no sales or additional purchases of common stock were disclosed. Apart from this routine director compensation grant, the filing contains no other material transactions or changes in ownership.
United Parks & Resorts Inc. (PRKS) filed a Form 4 on 07/02/2025 disclosing an equity grant to non-executive director Aayushi Dalal. The filing covers a 06/30/2025 transaction in which the director acquired 108 common shares—comprising 54 restricted stock units (RSUs) and 54 deferred stock units (DSUs)—under the company’s 2017 Omnibus Incentive Plan. The award vests 100% immediately; DSU shares will be issued three months after the director’s separation from service.
- Transaction code: “A� (award/grant)
- Price reported: $47.33 per share (grant-date fair value)
- Post-grant beneficial ownership: 5,466 PRKS shares held directly
- Reporting person role: Independent Director (not an officer or 10% owner)
The grant is routine board compensation and increases Dalal’s direct stake by roughly 2% relative to her prior holdings, a modest but positive alignment signal. No derivative securities were reported, and there is no indication that the transaction is part of a Rule 10b5-1 trading plan. The filing does not disclose broader financial results or strategic developments; its relevance is limited to corporate governance and insider-ownership monitoring.
On 30 June 2025, Wintrust Financial Corp. (WTFC) director Brian A. Kenney reported the acquisition of 420 common shares under the company’s Director’s Deferred Fee and Stock Plan, as disclosed in a Form 4 filing. The shares were credited at a price of $112.46, increasing Kenney’s direct beneficial ownership to 11,214 WTFC shares. The transaction is coded “A,� indicating an award rather than an open-market purchase, and no derivative securities were involved. While routine in nature, the filing slightly increases insider ownership and may be viewed as a signal of continued alignment between the director and shareholder interests.
Acacia Research Corp. (ACTG) � Form 4 filing: Director Gavin T. Molinelli received 8,380 shares of common stock on 30 Jun 2025 at an implied price of $3.58 per share. The stock grant was made in lieu of cash compensation for Q2-2025 board fees. Following the transaction, Molinelli’s total direct ownership increased to 150,987 shares. No dispositions or derivative transactions were reported, and no Rule 10b5-1 trading plan was indicated.
Because the shares were granted rather than purchased on the open market, the event signals board-level alignment but has limited immediate financial impact on the company. There is no effect on outstanding share count beyond routine equity compensation and no earnings or operational data were disclosed.